fair value 23c ready for 400% up, page-56

Kr,
PLZ read carefully to understand why I quote the previous transaction.

Whatever deal NSP done.....whatever positive news from the ann......you guys can find out some negative stuffs quoted 100 times. If everything as you expect to happen, SP is 46c, not 4.6c now, NSP currently is at critical "de-risking" stage---upside clearly 23c+ even $1 is possible considering the branches development potential.

India is the first, next will be China. You have to admit the india company must have done its DD.....the Asia fund have worked together with NSP for half year, then agreement just inked......6 monthes already----at least this investor knows PriME much much more than you and FX.

Their signature is worth 100000 times than you guys barking 10000 times.

quote my previous post.

"The LOI provides for a potential investment of up to S$20m by a significant Asian Life Sciences fund."

Seems this time $20m for 30% of Prime Biologics is fair, considering the previous deal. NSP will free carried 60%, once $20m investment done, NSP can easily sell another 10% for $6m cash.

quote:

Singapore: SGX-listed Luye Pharma Group is investing S$6 million (A$4.6 million) in NuSep's Singapore subsidiary Prime Biologics in exchange for a 10 percent interest in the company. Under the terms of the deal, NuSep will issue Luye with 6 million shares in Prime Biologics giving it a 10 percent shareholding. NuSep currently holds the remaining 90 percent, but expects to sell this and bring its holding down to 50 percent as additional investors subscribe for shares in Prime Biologics. The transaction to be executed through Luye Pharma's subsidiary A-Bio Pharma values Prime Biologics at S$60 million and is the first such investment by a pharma company in NuSep's "PrIME" technology. The deal will enable NuSep to establish a physical presence for Prime Biologics in Singapore. - See more at: http://www.biospectrumasia.com/biospectrum/news/3084/luye-pharma-invests-nuseps-prime-technology#.UbxyATtG18Q